Olema Oncology Fuels Breast Cancer Pipeline with $190M Offering
A substantial funding round positions Olema Oncology for growth, validating the potential of its novel breast cancer therapies and benefiting from positive momentum in the SERD market.
Olema Oncology Fuels Breast Cancer Pipeline with $190M Offering
NEW YORK, NY – November 19, 2025
Olema Oncology, a clinical-stage biopharmaceutical company focused on breast cancer treatment, today announced the pricing of a $190.0 million public offering. The offering of 10,000,000 shares of common stock, priced at $19.00 per share, provides a significant capital injection for the company as it advances its pipeline of novel therapies targeting estrogen receptor-positive (ER+) and HER2-negative breast cancer.
Funding a Promising Pipeline
The substantial funding round underscores investor confidence in Olema’s strategy and the potential of its lead candidate, palazestrant. Palazestrant is an orally available complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), designed to overcome resistance mechanisms commonly seen with existing endocrine therapies. Currently, palazestrant is being evaluated in two Phase 3 clinical trials – OPERA-01 and OPERA-02 – addressing critical unmet needs in both later-line and first-line treatment settings for advanced breast cancer.
“The financing provides Olema with the resources to accelerate clinical development and potentially bring a much-needed innovation to patients battling advanced breast cancer,” explained one industry analyst. “Palazestrant’s unique mechanism of action as a CERAN and SERD sets it apart, offering the potential to overcome resistance to current therapies.
📝 This article is still being updated
Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.
Contribute Your Expertise →